|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
107.21(B) |
Last
Volume: |
378,341 |
Avg
Vol: |
759,306 |
52
Week Range: |
$692.45 - $1071.19 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
191,758 |
236,826 |
311,409 |
468,643 |
Total Sell Value |
$188,359,854 |
$231,314,072 |
$294,701,490 |
$404,818,815 |
Total People Sold |
7 |
13 |
16 |
18 |
Total Sell Transactions |
16 |
39 |
65 |
127 |
End Date |
2024-04-04 |
2024-01-02 |
2023-07-04 |
2022-07-04 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Terifay Robert J |
SVP Commercial |
|
2012-07-27 |
4 |
OE |
$16.80 |
$918,700 |
D/D |
50,875 |
40,039 |
|
- |
|
Shooter Eric M |
Director |
|
2012-07-26 |
5 |
GA |
$0.00 |
$0 |
I/I |
5,000 |
2,500 |
|
- |
|
Sing George L |
Director |
|
2012-07-26 |
4 |
S |
$135.00 |
$675,000 |
D/D |
(5,000) |
137,772 |
|
- |
|
Sing George L |
Director |
|
2012-07-26 |
4 |
OE |
$18.80 |
$94,000 |
D/D |
5,000 |
142,772 |
|
- |
|
Powchik Peter |
SVP Clinical Development & Reg |
|
2012-07-26 |
4 |
AS |
$130.40 |
$916,953 |
D/D |
(7,019) |
15,144 |
|
- |
|
Shooter Eric M |
Director |
|
2012-07-25 |
5 |
GD |
$0.00 |
$0 |
I/I |
5,000 |
0 |
|
- |
|
Powchik Peter |
SVP Clinical Development & Reg |
|
2012-07-25 |
4 |
D |
$126.76 |
$1,011,672 |
D/D |
(7,981) |
22,163 |
|
- |
|
Powchik Peter |
SVP Clinical Development & Reg |
|
2012-07-25 |
4 |
OE |
$16.80 |
$252,000 |
D/D |
15,000 |
30,144 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2012-07-24 |
4 |
GD |
$0.00 |
$0 |
I/I |
59,841 |
19,950 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2012-07-12 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,860 |
164,049 |
|
- |
|
Yancopoulos George |
EVP CSO Pres REGN Res Lab |
|
2012-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
500,000 |
1,333,041 |
|
- |
|
Stahl Neil |
SVP Res & Dev Sciences |
|
2012-06-19 |
4 |
AS |
$115.60 |
$4,514,593 |
D/D |
(38,911) |
59,121 |
|
- |
|
Stahl Neil |
SVP Res & Dev Sciences |
|
2012-06-18 |
4 |
D |
$115.29 |
$6,475,609 |
D/D |
(56,168) |
98,032 |
|
- |
|
Stahl Neil |
SVP Res & Dev Sciences |
|
2012-06-18 |
4 |
OE |
$20.32 |
$1,932,005 |
D/D |
95,079 |
154,200 |
|
- |
|
Sing George L |
Director |
|
2012-05-31 |
4 |
S |
$134.74 |
$674,397 |
D/D |
(5,000) |
137,772 |
|
- |
|
Sing George L |
Director |
|
2012-05-30 |
4 |
S |
$134.00 |
$670,000 |
D/D |
(5,000) |
142,772 |
|
- |
|
Aberman Michael S |
VP Strategy and Investor Relat |
|
2012-05-24 |
4 |
OE |
$24.00 |
$12,000 |
D/D |
500 |
10,500 |
|
- |
|
Goldberg Murray A |
SVP Finance and Admin CFO Trea |
|
2012-05-21 |
4 |
OE |
$11.64 |
$235,978 |
D/D |
16,244 |
96,410 |
|
- |
|
Shooter Eric M |
Director |
|
2012-05-21 |
4 |
S |
$123.23 |
$2,226,540 |
D/D |
(18,000) |
0 |
|
- |
|
Shooter Eric M |
Director |
|
2012-05-21 |
4 |
OE |
$18.61 |
$392,980 |
D/D |
18,000 |
10,000 |
|
- |
|
Shooter Eric M |
Director |
|
2012-05-18 |
4 |
S |
$124.04 |
$248,080 |
D/D |
(2,000) |
0 |
|
- |
|
Shooter Eric M |
Director |
|
2012-05-18 |
4 |
OE |
$18.61 |
$37,220 |
D/D |
2,000 |
2,000 |
|
- |
|
Ryan Arthur F |
Director |
|
2012-05-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
7,000 |
60,355 |
|
- |
|
Goldberg Murray A |
SVP Finance and Admin CFO Trea |
|
2012-05-03 |
4 |
AS |
$132.96 |
$3,324,930 |
D/D |
(24,642) |
80,166 |
|
- |
|
Goldberg Murray A |
SVP Finance and Admin CFO Trea |
|
2012-05-02 |
4 |
D |
$136.37 |
$4,063,281 |
D/D |
(29,796) |
104,808 |
|
- |
|
2433 Records found
|
|
Page 70 of 98 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|